211 related articles for article (PubMed ID: 2122928)
1. Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.
Farace F; Mathiot C; Brandely M; Tursz T; Dorval T; Pouillart P; Triebel F; Hercend T; Fridman WH
Clin Exp Immunol; 1990 Nov; 82(2):194-9. PubMed ID: 2122928
[TBL] [Abstract][Full Text] [Related]
2. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
3. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
[TBL] [Abstract][Full Text] [Related]
5. Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.
Sano T; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Sakurai M; Takahashi H; Nakano H; Nakagawa K
Jpn J Cancer Res; 1988 Jan; 79(1):131-43. PubMed ID: 3128501
[TBL] [Abstract][Full Text] [Related]
6. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
8. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
[TBL] [Abstract][Full Text] [Related]
9. A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-gamma and recombinant interleukin-2 in patients with cancer.
Taylor CW; Chase EM; Whitehead RP; Rinehart JJ; Neidhart JA; Gonzalez R; Bunn PA; Hersh EM
J Immunother (1991); 1992 Apr; 11(3):176-83. PubMed ID: 1515422
[TBL] [Abstract][Full Text] [Related]
10. Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.
Yoneda K; Yamamoto T; Ueta E; Osaki T
J Clin Immunol; 1992 Jul; 12(4):289-99. PubMed ID: 1512302
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignancies.
Bukowski RM; Sergi JS; Budd GT; Murthy S; Tubbs R; Gibson V; Bauer L; Stanley J; Gautam S; Finke J
J Immunother (1991); 1991 Dec; 10(6):432-9. PubMed ID: 1768677
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
13. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
15. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.
Silagi S; Dutkowski R; Schaefer A
Int J Cancer; 1988 Feb; 41(2):315-22. PubMed ID: 3123404
[TBL] [Abstract][Full Text] [Related]
16. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Murray C; Cochran K; Cameron C; Wang E; Schow PW; Daley JF; Ritz J
Blood; 1992 Jan; 79(2):517-26. PubMed ID: 1730094
[TBL] [Abstract][Full Text] [Related]
17. Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2.
Kolitz JE; Welte K; Wong GY; Holloway K; Merluzzi VJ; Engert A; Bradley EC; Konrad M; Polivka A; Gabrilove JL
J Biol Response Mod; 1987 Aug; 6(4):412-29. PubMed ID: 3498011
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
19. Hematotoxicity of interleukin-2 in man: clinical effects and comparison of various treatment regimens.
Schomburg A; Kirchner H; Atzpodien J
Acta Haematol; 1993; 89(3):119-31. PubMed ID: 8362600
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of combined recombinant interleukin-2 with levamisole in patients with advanced malignant disease.
Call TG; Creagan ET; Frytak S; Buckner JC; van Haelst-Pisani C; Homburger HA; Katzmann JA
Am J Clin Oncol; 1994 Aug; 17(4):344-7. PubMed ID: 8048398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
